---
title: "Surya Pharmaceutical Ltd (SURYAPHARM) — Share Price, Financials & Analysis"
symbol: "SURYAPHARM"
company: "Surya Pharmaceutical Ltd"
canonical: "https://tapetide.com/stocks/SURYAPHARM"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T19:29:52.743Z"
---

# Surya Pharmaceutical Ltd (SURYAPHARM)

Canonical page: https://tapetide.com/stocks/SURYAPHARM

## Company

- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** suryapharma.com

## About

Surya Pharmaceuticals Ltd. ventures as a pharmaceutical company. The businesses include Contract Manufacturing, Custom Synthesis, FTE Research, and the manufacture and marketing of pharmaceuticals products and services to clients worldwide. Surya Pharmaceuticals' wide range of product portfolio includes Active Pharmaceutical Ingredients (APIs), Fine Intermediates, Finished Drug Formulations (FDFs), Phyto Pharmaceuticals and CRAMS.

## Latest Price

## Key Insights

### Weaknesses

- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -34.2% over past five years.
- Company has a low return on equity of -51.2% over last 3 years.
- Company has high debtors of 1,363 days.
- Working capital days have increased from 2,034 days to 5,556 days

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | 126% | — | — |
| revenue growth | -178% | -62% | -34% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | -15 | 6 | 5 | 1 | 2 | 0 | 0 | 0 |
| Expenses | 110 | 9 | 8 | 618 | 13 | 2 | 2 | 1 |
| Operating Profit | -125 | -3 | -3 | -617 | -11 | -1 | -1 | -1 |
| OPM % | — | -54 | -69 | -102843 | -492 | -251 | -293 | — |
| Other Income | -18 | 0 | 0 | -219 | 0 | 0 | 0 | 0 |
| Interest | 38 | 62 | 69 | 16 | 108 | 0 | 0 | 0 |
| Depreciation | 34 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Profit before tax | -215 | -81 | -88 | -868 | -134 | -17 | -17 | -17 |
| Tax % | 0 | 0 | 0 | 0 | -331 | 0 | 0 | 0 |
| Net Profit | -215 | -81 | -88 | -868 | 310 | -17 | -17 | -17 |
| EPS in Rs | -10.6 | -3.97 | -4.35 | -42.8 | 15.28 | -0.83 | -0.84 | -0.85 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 239 | 283 | 486 | 723 | 1134 | 1600 | 1623 | 60 | 3 |
| Expenses | 192 | 231 | 400 | 602 | 973 | 1337 | 1765 | 214 | 18 |
| Operating Profit | 47 | 52 | 86 | 120 | 161 | 263 | -142 | -154 | -14 |
| OPM % | 20 | 18 | 18 | 17 | 14 | 16 | -9 | -255 | -476 |
| Other Income | 0 | 3 | 5 | 1 | 13 | 3 | -38 | -35 | 0 |
| Interest | 14 | 16 | 26 | 41 | 62 | 108 | 179 | 207 | 108 |
| Depreciation | 6 | 8 | 9 | 16 | 21 | 27 | 35 | 62 | 63 |
| Profit before tax | 27 | 30 | 56 | 64 | 90 | 132 | -393 | -459 | -185 |
| Tax % | 21 | 22 | 26 | 12 | 16 | 24 | -31 | -34 | — |
| Net Profit | 21 | 24 | 42 | 56 | 76 | 100 | -273 | -302 | 259 |
| EPS in Rs | — | 16.37 | 28.83 | 38.8 | 52.57 | 5.2 | -13.47 | -14.89 | 12.76 |
| Dividend Payout % | 0 | 0 | 3 | 3 | 3 | 3 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 11 | 14 | 14 | 14 | 14 | 19 | 20 | 20 |
| Reserves | 80 | 124 | 164 | 216 | 289 | 501 | 227 | -75 |
| Borrowings | 148 | 196 | 318 | 501 | 708 | 1441 | 1754 | 2009 |
| Other Liabilities | 54 | 60 | 124 | 218 | 375 | 205 | 126 | 63 |
| Total Liabilities | 293 | 394 | 621 | 949 | 1386 | 2166 | 2128 | 2017 |
| Fixed Assets | 62 | 81 | 162 | 213 | 229 | 404 | 728 | 671 |
| CWIP | 31 | 61 | 30 | 88 | 199 | 232 | 7 | 8 |
| Investments | 0 | 0 | 0 | 0 | 6 | 26 | 34 | 16 |
| Other Assets | 200 | 251 | 429 | 648 | 953 | 1504 | 1358 | 1323 |
| Total Assets | 293 | 394 | 621 | 949 | 1386 | 2166 | 2128 | 2017 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 24 | -5 | 68 | -8 | 165 | 69 | 386 | 166 |
| Cash from Investing Activity | -48 | -56 | -54 | -121 | -144 | -245 | -150 | -8 |
| Cash from Financing Activity | 61 | 25 | 13 | 103 | -11 | 174 | -241 | -160 |
| Net Cash Flow | 38 | -36 | 26 | -25 | 10 | -2 | -6 | -3 |
| Free Cash Flow | -24 | -62 | 9 | -133 | 18 | -165 | 262 | 157 |
| CFO/OP | 58 | 0 | 85 | 6 | 108 | 32 | -356 | -201 |

### Ratios

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 77 | 95 | 62 | 69 | 49 | 66 | 53 | 1363 |
| Inventory Days | 172 | 235 | 238 | 247 | 271 | 309 | 179 | 1254 |
| Days Payable | 63 | 63 | 88 | 117 | 108 | 20 | 10 | 56 |
| Cash Conversion Cycle | 185 | 266 | 212 | 199 | 212 | 355 | 222 | 2561 |
| Working Capital Days | 171 | 251 | 213 | 220 | 184 | 308 | 238 | 5556 |
| ROCE % | — | 16 | 20 | 18 | 17 | 16 | -11 | -12 |

## Filings & Documents

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2013 from nse](https://archives.nseindia.com/annual_reports/AR_3056_SURYAPHARM_2012_2013_06122013094827.zip) |
| from nse | [Annual Report 2012 from nse](https://archives.nseindia.com/annual_reports/AR_SURYAPHARM_2011_2012_14092012094316.zip) |
| from nse | [Annual Report 2011 from nse](https://archives.nseindia.com/annual_reports/AR_SURYAPHARM_2010_2011_15062012101738.zip) |
| from nse | [Annual Report 2010 from nse](https://archives.nseindia.com/annual_reports/AR_SURYAPHARM_2009_2010_17092010120000.zip) |
| from bse | [Annual Report 2012 from bse](https://www.bseindia.com/bseplus/AnnualReport//5325160312.pdf) |
| from bse | [Annual Report 2011 from bse](https://www.bseindia.com/bseplus/AnnualReport//5325160311.pdf) |
| from bse | [Annual Report 2010 from bse](https://www.bseindia.com/bseplus/AnnualReport//5325160310.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:29:52.743Z.